在慢性炎症性风湿性疾病中使用的瘤坏死α (TNF-α) 反对者:风险及其最小化措施
Rim Lakhmiri1, Yahia Cherrah1, Samira Serragui1
1Pharmaco-Epidemiology and Pharmaco-Economics Research Team - Laboratory of Pharmacology and Toxicology - Faculty of Medicine and Pharmacy -Mohammed V University of Rabat, Morocco.
瘤坏死因子α (TNF-α) 抑制剂有效地控制炎症性风湿症,但会带来感染和恶性瘤等风险. 风险管理计划详细说明了减轻这些不良事件的措施,确保了患者的安全.
科学领域:
- 类风湿病学 类风湿病学
- 药物监督 药物监督 药物监督
- 临床风险管理临床风险管理
背景情况:
- 瘤坏死因子α (TNF-α) 抑制剂对于治疗慢性炎症性类风湿性疾病至关重要.
- 它们的使用与重大不良事件有关,包括感染,恶性瘤和心血管并发症.
研究的目的:
- 审查TNF-α抑制剂的当前应用,风险和安全管理.
- 分析风险最小化措施的实施和有效性.
主要方法:
- 对TNF-α抑制剂治疗,风险和风险管理计划 (RMP) 的综合文献综述.
- 在RMP中分析常规和额外的风险最小化策略.
- 评估实际实施和风险管理实践的有效性.
主要成果:
- TNF-α抑制剂提供治疗益处,但需要仔细评估风险.
- 风险管理计划概述了基本的安全措施,包括例行和额外的干预措施.
- 风险最小化策略的有效性评估对于患者安全至关重要.
结论:
- TNF-α 抑制剂需要强大的风险管理策略来平衡有效性和安全性.
- 对医疗保健提供者和患者来说,了解和实施降低风险的措施至关重要.
- 持续评估风险管理实践对于优化风湿性疾病患者的治疗结果至关重要.
更多相关视频
16:07Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method
Published on: September 16, 2017
04:47Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
Published on: October 27, 2023
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
